TherapeuticsMD
TXMD
37 hedge funds and large institutions have $5.61M invested in TherapeuticsMD in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 5 closing their positions.
33% more call options, than puts
Call options by funds: $24K | Put options by funds: $18K
2% more capital invested
Capital invested by funds: $5.49M → $5.61M (+$121K)
0.26% less ownership
Funds ownership: 29.57% → 29.31% (-0.26%)
3% less funds holding
Funds holding: 38 → 37 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.4K |
| 2 |
CPA
Capital Performance Advisors
Walnut Creek,
California
|
+$1.04K |
| 3 |
Morgan Stanley
New York
|
+$205 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$12 |
| 5 |
AssetMark Inc
Concord,
California
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$23.1K |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
-$19.3K |
| 3 |
BlackRock
New York
|
-$15.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.43K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.74K |
TXMD Hedge Fund Activity: Q3 2024 in Review
37 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2024, worth a combined $5.61M — up 2.2% from $5.49M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TXMD and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $22.4K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $23.1K sold.
- 37 institutional investors held TherapeuticsMD (TXMD) as of Q3 2024, down from 38 in Q2 2024.
- Funds reported $5.61M of TherapeuticsMD stock for Q3 2024, up 2.2% quarter-over-quarter.
- 4 funds opened new TherapeuticsMD positions in Q3 2024 and 5 closed out, a net change of -1 holder.
- The largest TherapeuticsMD buyer in Q3 2024 was Geode Capital Management, an estimated $22.4K added.
- The largest TherapeuticsMD seller in Q3 2024 was Two Sigma Securities, an estimated $23.1K sold.
Based on aggregated 13F filings for Q3 2024.